Cargando…
Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
Background: Direct-acting antivirals (DAAs) opened a new era in the management of hepatitis C virus (HCV)-associated liver disease. However, hepatic cancer screening should not be stopped after obtaining a sustained virologic response (SVR). Current guidelines offer several treatment options for hep...
Autores principales: | Mercan-Stanciu, Adriana, Isac, Teodora, Rababoc, Razvan, Rusie, Daniel, Toma, Letitia, Vacaroiu, Ileana Adela, Tulin, Raluca, Iliescu, Elena Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246468/ https://www.ncbi.nlm.nih.gov/pubmed/35800821 http://dx.doi.org/10.7759/cureus.25487 |
Ejemplares similares
-
Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals
por: Rusie, Daniel, et al.
Publicado: (2022) -
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
por: Iliescu, Elena Laura, et al.
Publicado: (2020) -
Epigenetics in inflammatory liver diseases: A clinical perspective (Review)
por: Isac, Teodora, et al.
Publicado: (2022) -
Calprotectin in viral systemic infections—COVID-19 versus hepatitis C virus
por: Toma, Letitia, et al.
Publicado: (2021) -
Mesenteric Ischemia in a Patient with Essential Thrombocythemia: Does COVID-19 Play Any Role? A Case Report and Overview of the Literature
por: Cotorogea-Simion, Mihail, et al.
Publicado: (2022)